Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 30Gynecologic 13Thoracic 11Dermatologic 10Genitourinary 9Head & Neck 7Other solid neoplasm 6Breast 4Lymphoid 3CNS 3Sarcoma 2Other hematologic neoplasm 2NET 2Endocrine 2Plasma cell 1

Conditions

Lymphoma 2569Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia, Lymphocytic, Chronic, B-Cell 1771Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1596Leukemia 1170Hodgkin Disease 1127Lymphoma, Mantle-Cell 1110Burkitt Lymphoma 887Leukemia, Myeloid, Acute 884Lymphoma, B-Cell, Marginal Zone 788Recurrence 777Multiple Myeloma 744Lymphoma, B-Cell 702Myelodysplastic Syndromes 614Neoplasms 492Lymphoma, T-Cell, Cutaneous 479Waldenstrom Macroglobulinemia 470Lymphoma, Large-Cell, Immunoblastic 456Mycosis Fungoides 383Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Lymphoma, Large-Cell, Anaplastic 362Sezary Syndrome 321Lymphoma, T-Cell, Peripheral 320Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307Hematologic Neoplasms 298Myeloproliferative Disorders 288Neoplasms, Plasma Cell 270Blast Crisis 261

Interventions

Nivolumab 2Specimen Handling 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Turcot syndrome × Lymphoid × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT03894618 2025-04-02

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Shattuck Labs, Inc.

Phase 1 Completed
49 enrolled 32 charts
DermatologicGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Hodgkin Disease, Melanoma, Lymphoma, Large B-Cell, Diffuse

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡